The Yervoy REMS
This article was originally published in RPM Report
Executive Summary
FDA approved Bristol-Myers Squibbs melanoma therapy with a mandatory communication plan--despite the Oncology drug group's overall skepticism about the value of REMS in a class where black box warnings are standard. Here is FDA's outline of the REMSrequirements for Yervoy.